- Home
- GROV vs COCH Comparison
GROV vs COCH Comparison
Compare GROV & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROV | COCH |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | 295 | 47 |
| Industry | Package Goods/Cosmetics | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 51.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GROV | COCH |
|---|---|---|
| Price | $1.09 | $0.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.60 | ★ $6.00 |
| AVG Volume (30 Days) | 33.7K | ★ 311.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.36 |
| 52 Week High | $1.60 | $1.89 |
Technical Indicators
Market Signals| Indicator | GROV | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 51.93 |
| Support Level | $1.07 | $0.64 |
| Resistance Level | $1.33 | $0.74 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 41.67 | 41.37 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.